## Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology

**Supplemental table S1.** Treatment modalities registered for patients with and without a registration of curative treatment intention

Curative intention	n	RNU	Segmental resection	Nephrectomy only	Endoluminal resection/coagulation	BCG
Yes	1507	1160 (77 %)	149 (9.9 %)	60 (4.0 %)	122 (8.1 %)	17 (1.1 %)
No	617	120 (19 %)	14 (2.3 %)	18 (2.9 %)	22 (3.6 %)	6 (1.0 %)

RNU, radical nephroureterectomy; BCG, Bacillus Calmette-Guérin

Supplemental table S2. Pathologic tumour classification in patients treated with curative intention

		Renal pelvis N= 872	Ureter N= 635
	Т0	8 (0.9%)	18 (2.8%)
	Tis	17 (1.9%)	37 (5.8%)
	Ta	302 (35%)	259 (41%)
	T1	143 (16.4%)	83 (13%)
pT-stage	T2	86 (9.9%)	120 (19%)
	Т3	264 (30%)	107 (17%)
	T4	46 (5.3%)	6 (0.9%)
	Tx	6 (0.7%)	5 (0.8%)
	N0/Nx <sup>a</sup>	802 (92%)	604 (95%)
pN-stage	N1	34 (3.9%)	15 (2.4%)
	N2	36 (4.1%)	16 (2.5%)
N4 4	M0/Mx	835 (96%)	620 (98%)
pM-stage	M1	37 (4.2%)	15 (2.4%)
	LMP	3 (0.3%)	8 (1.3%)
	G1	98 (11%)	97 (15%)
n Condo	G2	307 (35%)	225 (35%)
p-Grade	G3	440 (51%)	266 (42%)
	Gx	21 (2.4%)	29 (4.6%)
	G0	3 (0.3%)	10 (1.6%)

<sup>&</sup>lt;sup>a</sup> The proportion of lymph node dissection performed is not available

**Supplemental table S3.** Cross-table of cT- and pT-stage for 467 patients with a preoperative biopsy treated with radical nephroureterectomy or segmental ureteric resection with curative treatment intention

	pTa/Tis	pT1	pT2	pT3	pT4
cTa/Tis	173 (61%)	34 (12%)	30 (11%)	34 (12%)	1 (0.4%)
cT1	6 (7.4%)	50 (62%)	9 (11%)	13 (16%)	0 (0.0%)
cT2	0 (0.0%)	0 (0.0%)	28 (80%)	4 (11%)	2 (5.7%)
сТ3	3 (4.4%)	0 (0.0%)	0 (0.0%)	63 (93%)	1 (1.5%)
cT4	0 (0.0%)	1 (6.2%)	0 (0.0%)	1 (6.2%)	14 (88%)
cTx	6 (26%)	5 (22%)	3 (13%)	9 (39%)	0 (0.0%)

Percentages per row may not add up to 100 since pT0 is not represented in the cross-table.

**Supplemental table S4.** Cross-table of clinical and pathologic tumour grade (WHO 1999) for 467 patients with a preoperative biopsy treated with radical nephroureterectomy or segmental ureteric resection with curative treatment intention.

	pLMP	pG1	pG2	pG3	pGx
cLMP	0 (0.0%)	3 (75%)	0 (0.0%)	1 (25%)	0 (0.0%)
cG1	1 (1.1%)	48 (53%)	27 (30%)	9 (10%)	4 (4.4%)
cG2	0 (0.0%)	10 (5.6%)	127 (72%)	32 (18%)	5 (2.8%)
cG3	2 (0.9%)	2 (0.9%)	13 (5.8%)	197 (88%)	6 (2.7%)

Percentages per row may not add up to 100 since pG0 is not represented in the cross-table.